Drug intelligence / Profile preview

ES008-a

Development stage: Preclinical
Lead developer: Elpiscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ES008-a is a high-affinity, specific monoclonal antibody designed to block the Leukocyte Immunoglobulin-like receptor B1 (LILRB1), an inhibitory receptor expressed on various immune cells. Developed by Elpiscience Biopharmaceuticals, ES008-a disrupts the interaction between LILRB1 and its ligands, including HLA-G and HLA-A2, which are often exploited by tumors to evade immune detection. By blocking this checkpoint, the antibody enhances anti-tumor activity by promoting macrophage-mediated phagocytosis, restoring the cytotoxic potential of natural killer (NK) cells, and boosting the effector functions of CD8+ T cells. It is currently under investigation for the treatment of solid tumors.

Targets

LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)

Beyond the preview

Go deeper on ES008-a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ES008-a.

Explore the full profile